These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 10522170)

  • 1. Maker of growth hormone feels long arm of law.
    Nordenberg T
    FDA Consum; 1999; 33(5):33. PubMed ID: 10522170
    [No Abstract]   [Full Text] [Related]  

  • 2. Not as easy as it may appear: using radio frequency identification technology to fulfill the Prescription Drug Marketing Act's elusive pedigree requirement.
    Asamoah AK
    Food Drug Law J; 2006; 61(2):385-418. PubMed ID: 16903035
    [No Abstract]   [Full Text] [Related]  

  • 3. Major issues in marketing regulation.
    Pines WL
    Food Drug Law J; 1997; 52(3):297-302. PubMed ID: 10343028
    [No Abstract]   [Full Text] [Related]  

  • 4. The future of off-label marketing regulations in the post-Sorrell era.
    Iraggi J
    Seton Hall Law Rev; 2013; 43(3):1137-63. PubMed ID: 23802338
    [No Abstract]   [Full Text] [Related]  

  • 5. Sword or shield? An overview and competitive analysis of the marketing of "authorized generics".
    Zain S
    Food Drug Law J; 2007; 62(4):739-77. PubMed ID: 18557229
    [No Abstract]   [Full Text] [Related]  

  • 6. The First Amendment and FDA restrictions on off-label uses: the call for a new approach.
    Leghorn J; Brophy E; Rother P
    Food Drug Law J; 2008; 63(2):391-406. PubMed ID: 18561466
    [No Abstract]   [Full Text] [Related]  

  • 7. Drug marketing exclusivity under United States and European Union law.
    Junod V
    Food Drug Law J; 2004; 59(4):479-518. PubMed ID: 15875347
    [No Abstract]   [Full Text] [Related]  

  • 8. Unlabeled drug samples and the learned intermediary: the case for drug company liability without preemption.
    Poser S
    Food Drug Law J; 2007; 62(4):653-94. PubMed ID: 18557225
    [No Abstract]   [Full Text] [Related]  

  • 9. Criminal conviction for distribution of a drug not approved by the FDA.
    Brushwood DB
    Am J Hosp Pharm; 1991 Apr; 48(4):747-9. PubMed ID: 2042679
    [No Abstract]   [Full Text] [Related]  

  • 10. Appeal court grants Genentech's growth market to Novo Nordisk.
    Kling J
    Nat Biotechnol; 1997 May; 15(5):403. PubMed ID: 9131605
    [No Abstract]   [Full Text] [Related]  

  • 11. Remarks at the Food and Drug Law Institute's 48th Annual Conference.
    Niedelman SM
    Food Drug Law J; 2005; 60(2):117-26. PubMed ID: 16097089
    [No Abstract]   [Full Text] [Related]  

  • 12. [Drug counterfeiting and counter measures. Study by the Hungarian National Alliance Against Drug Counterfeiting].
    Psychiatr Hung; 2009; 24(3):205-14. PubMed ID: 20017282
    [No Abstract]   [Full Text] [Related]  

  • 13. Recent developments in direct consumer advertising of attention disorder stimulants and creating limits to withstand constitutional scrutiny.
    Strawn MN
    J Contemp Health Law Policy; 2003; 19(2):495-520. PubMed ID: 14748255
    [No Abstract]   [Full Text] [Related]  

  • 14. Legalized importation of Canadian prescription drugs: short-term solution to a long-term problem.
    Teufel AT
    J Contemp Health Law Policy; 2006; 22(2):383-408. PubMed ID: 17117702
    [No Abstract]   [Full Text] [Related]  

  • 15. Regulating manufacturer-affiliated communication in the information age.
    Schulman KA; Abernethy DR; Rathore SS; Woosley RL
    Clin Pharmacol Ther; 1999 Jun; 65(6):593-7. PubMed ID: 10391664
    [No Abstract]   [Full Text] [Related]  

  • 16. Forbidden and Permitted Statements about Medications--Loosening the Rules.
    Avorn J; Sarpatwari A; Kesselheim AS
    N Engl J Med; 2015 Sep; 373(10):967-73. PubMed ID: 26332553
    [No Abstract]   [Full Text] [Related]  

  • 17. FDA, industry collaborate to strengthen painkiller restrictions.
    Sipkoff M
    Manag Care; 2009 Apr; 18(4):10-1. PubMed ID: 19472560
    [No Abstract]   [Full Text] [Related]  

  • 18. The new drug marketing: a consumer protection perspective.
    Woodward D
    Food Drug Law J; 1996; 51(4):637-50. PubMed ID: 11797733
    [No Abstract]   [Full Text] [Related]  

  • 19. The FDA and congress: differing agendas?
    Lipman AG
    J Pain Palliat Care Pharmacother; 2010 Jun; 24(2):116-7. PubMed ID: 20504131
    [No Abstract]   [Full Text] [Related]  

  • 20. Understanding government regulation of the marketing and advertising of medical devices, drugs, and biologics: the challenges of the Internet.
    Reichertz PS
    Food Drug Law J; 1997; 52(3):303-8. PubMed ID: 10343029
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.